Pioneers in Neuroscience A LETTER FROM ALPHONSE GALDES, PH.D., HEAD OF PHARMACEUTICAL OPERATIONS AND TECHNOLOGY AT BIOGEN: IT’S TIME FOR COMPANIES TO ACT LIKE THE CLIMATE CRISIS IS A HEALTH CRISIS Read more Search Submit Alzheimer's Disease News Our Stories Pipeline Investors Careers DOMINIC WALSH | DECODING THE PATHOLOGY OF ALZHEIMER’S Since amyloid beta and tau were first discovered more than 100 years ago, scientists have been trying to understand their role in Alzheimer’s disease and how modulating genetic risk factors for developing Alzheimer’s can address the disease. Hear from Dominic Walsh, head of Biogen’s Neurodegeneration Research Unit. Read more THE FUTURE OF MEDICINE | A CONVERSATION WITH ALFRED SANDROCK Biogen’s Executive Vice President, Research and Development, Alfred ‘Al’ Sandrock, M.D., Ph.D., on how our growing understanding of genetics coupled with the use of biomarkers and measurement tools will provide us with insights that could potentially revolutionize the field of medicine and drug development. Read more AMYOTROPHIC LATERAL SCLEROSIS (ALS) AT BIOGEN We aspire to improve the lives of people living with and caring for those with ALS. More information BIOGEN ANNOUNCES TOPLINE RESULTS FROM THE TOFERSEN PHASE 3 STUDY AND ITS OPEN-LABEL EXTENSION IN SOD1-ALS Read more BIOGEN DIGITAL HEALTH Biogen Digital Health aspires to transform patients’ lives and Biogen by making personalized & digital medicine in neuroscience a reality. Read more SOD1-ALS: TOFERSEN EARLY ACCESS PROGRAM (EAP) Read more HEALTHY CLIMATE, HEALTHY LIVES™ Biogen marks one-year anniversary of $250 million, 20-year commitment to accelerate action on the greatest challenges of our time: climate, health and equity. Read more U.S. FDA APPROVES ADUHELM™ (ADUCANUMAB-AVWA) FOR ALZHEIMER’S DISEASE Biogen and Eisai receive FDA accelerated approval for a new therapy targeting amyloid beta plaque. More information 11/22/21 11:00 AM EST Statement on JAMA Neurology Publication about Amyloid-Related Imaging Abnormalities in Two Phase 3 Studies Evaluating Aducanumab in Early Alzheimer’s Disease View all news BIOGEN UPDATES DELIVERED TO YOUR INBOX Sign up today UPDATE ON ADUCANUMAB ACCESS PROGRAMS OUTSIDE OF THE UNITED STATES Read more FIND DISEASE INFORMATION Select DIVERSITY, EQUITY AND INCLUSION Biogen is committed to the power of diversity – in our organization and among our patients and customers. Diversity is an essential asset of complementary strengths and perspectives from which all benefit, and which must unite us, not divide us. Learn more about our commitment WHERE SCIENCE MEETS HUMANITY Science that transforms patient lives. Science that seeks to solve societal problems. Science that acts with purpose. Science that is inspired by the diversity and passion of our people. Discover where science meets humanity at Biogen. Read our stories “Our goal is to deliver innovative therapies for patients and invest in the areas of highest return to deliver long-term value to our stockholders.” Michel Vounatsos, CEO More OUR PEOPLE Meet Jeffrey. Hear from Jeffrey on the work of Diversity, Equity & Inclusion at Biogen. More FOLLOW US ON SOCIAL MEDIA Twitter LinkedIn Facebook YouTube Investors Careers News Releases Our Stories Receive Our Updates Contact Us Follow us: Terms & Conditions Privacy Policy Notice to CA Residents Cookie Policy Forward-Looking Statement Community Guidelines © 2021 Biogen